Valuation: Galapagos NV

Market Cap 1.77B 2.03B 2.03B 1.63B 1.52B 2.88B 193B 2.92B 19.56B 7.6B 94.9B 7.61B 7.45B 327B P/E 2026 *
-9.25x
P/E 2027 * -10.7x
Enterprise Value -882M -1.01B -1.01B -810M -755M -1.43B -96.04B -1.45B -9.73B -3.78B -47.21B -3.79B -3.7B -163B EV / Sales 2026 *
-5.86x
EV / Sales 2027 * -5.09x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-12
Director of Finance/CFO 43 2025-07-06
Chief Tech/Sci/R&D Officer 61 2026-06-07
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-12
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%+6.89%+2.76%+7.65% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+2.38%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.32%+1.58%+14.34%+19.26% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +1.64%+6.13%+71.68%+104.05% 26.92B
Weighted average by Cap. +1.74%+6.58%+89.14%+131.73%

Financials

2026 *2027 *
Net sales 150M 172M 172M 138M 129M 244M 16.39B 248M 1.66B 645M 8.06B 646M 632M 27.76B 132M 151M 151M 121M 113M 215M 14.39B 218M 1.46B 567M 7.07B 567M 555M 24.37B
Net income -261M -298M -298M -240M -223M -424M -28.4B -430M -2.88B -1.12B -13.96B -1.12B -1.1B -48.1B -145M -166M -166M -133M -124M -236M -15.81B -239M -1.6B -623M -7.77B -623M -610M -26.78B
Net Debt -2.65B -3.04B -3.04B -2.44B -2.27B -4.31B -289B -4.38B -29.29B -11.38B -142B -11.4B -11.15B -490B -2.44B -2.8B -2.8B -2.25B -2.09B -3.97B -266B -4.03B -26.97B -10.49B -131B -10.5B -10.27B -451B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B